Posted by Michael Wonder on 06 Feb 2024
BridgeBio Pharma announces US FDA acceptance of new drug application for acoramidis for the treatment of patients with transthyretin amyloid cardiomyopathy
5 February 2024 - Accepted with Prescription Drug User Fee Act action date of 29 November 2024; the FDA not currently planning to hold an advisory committee meeting to discuss application.
BridgeBio Pharma today announced that the US FDA has accepted for filing the Company’s new drug application for acoramidis, an investigational drug for the treatment of transthyretin amyloid cardiomyopathy.
